EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Mabion's Enterprise Value is zł244.7 Mil.
Mabion's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was zł53.2 Mil. Therefore, Mabion's EV-to-EBIT for today is 4.60.
The historical rank and industry rank for Mabion's EV-to-EBIT or its related term are showing as below:
LTS:0QGW'
s EV-to-EBIT Range Over the Past 10 Years
Min: -3023.04 Med: -15.91 Max: 71942.23
Current: 4.61
During the past 13 years, the highest EV-to-EBIT of Mabion was 71942.23. The lowest was -3023.04. And the median was -15.91.
LTS:0QGW's EV-to-EBIT is ranked better than 58.16% of 423
companies
in the Biotechnology industry
Industry Median: 10.04
vs LTS:0QGW: 4.61
The historical data trend for Mabion's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Mabion's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mabion's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mabion's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Mabion's EV-to-EBIT falls into.
Mabion's current Enterprise Value is zł244.7 Mil.
Mabion's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł53.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mabion (LTS:0QGW) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Mabion's Enterprise Value for the quarter that ended in Mar. 2024 was zł583.1 Mil.
Mabion's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł53.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mabion EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Mabion's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0QGW has been successfully added to your 